- Cell surface ligands and receptors are the most valuable therapeutic targets, as more than one-third of all FDA-approved drugs targeting these proteins
- Functional proteomics technologies are designed to identify intracellular protein-protein interaction networks but not ligand-receptor interactions
- Our ligandomics is the only technology to globally identify cell-wide ligands with simultaneous binding activity quantification
- Our Comparative ligandomics is the only technology for systematic map of disease-selective cellular ligands.
- Therapies targeting disease-selective ligands have the advantages of high efficacy, minimal adverse side effects on normal cells, wide therapeutic windows, low drug attrition rates and reduced R&D costs.
|
